H.C. Wainwright reiterates Alnylam stock rating on drug differentiation

H.C. Wainwright has reaffirmed its Buy rating and $455 price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. The biotech company, valued at $32.9 billion, is currently trading at $246.11, with analysts forecasting price targets between $230 and $536. This decision followed the presentation of primary results on August 28 at the European Society of Cardiology Congress 2026 in Munich.

The results, from the primary outcomes of Ionis Pharmaceuticals’ and AstraZeneca’s antisense oligonucleotide eplontersen, indicated a rate ratio of 0.89 when comparing 381 cardiovascular events in 210 eplontersen patients versus 392 events in 231 placebo patients through Week 140. At the investor event held by Alnylam on August 30, CEO Yvonne Greenstreet and Chief R&D Officer Pushkal Garg highlighted that AMVUTTRA met all ten endpoints in the Phase 3 HELIOS-B trial, achieving a 36% reduction in all-cause mortality at 42 months.

Management noted that eplontersen had approximately 11 points lower TTR knockdown compared to AMVUTTRA, both in mean and median measures. The Phase 3 TRITON-CM trial employs nucresiran, a next-generation silencer with over 95% knockdown, and focuses on earlier-stage patients with an event-driven design targeting all-cause mortality and recurrent cardiovascular events.

Analysts like Stifel and Truist Securities have also maintained their Buy ratings for Alnylam, with price targets of $318.00 and $315.00 respectively, while TD Cowen and BMO Capital have upheld Buy ratings, emphasizing the effectiveness of TTR silencing strategies based on the HELIOS-B Taf subgroup analysis. The overall consensus among the analyst community indicates strong interest in Alnylam's ongoing trials and strategies.